



E-HEALTH “STANDINGTALL” BALANCE EXERCISE FOR FALL PREVENTION IN OLDER PEOPLE: RESULTS OF A TWO-YEAR RANDOMISED CONTROLLED TRIAL

Journal:	<i>BMJ</i>
Manuscript ID	BMJ-2020-063155
Article Type:	Research
BMJ Journal:	BMJ
Date Submitted by the Author:	18-Nov-2020
Complete List of Authors:	<p>Delbaere, Kim; University of New South Wales, Neuroscience Research Australia; University of New South Wales, School of Population Health Valenzuela, Trinidad; The University of Sydney, Physical Activity, Lifestyle, Ageing and Wellbeing Faculty Research Group, Faculty of Medicine and Health; Universidad Finis Terrae, Exercise Science Laboratory, School of Kinesiology</p> <p>Lord, Stephen; Neuroscience Research Australia, Falls and Balance Research Group; University of New South Wales, Neuroscience Research Australia</p> <p>Clemson, Lindy; University of Sydney, Faculty of Health Sciences</p> <p>Zijlstra, Gertrud; Maastricht University/CAPHRI, Health Services Research</p> <p>Close, Jacqueline; University of New South Wales, Neuroscience Research Australia; University of New South Wales, Prince of Wales Hospital Clinical School</p> <p>Wai-Chun Lung, Thomas ; The George Institute for Global Health; The University of Sydney Faculty of Medicine and Health, School of Public Health</p> <p>Woodbury, Ashley; University of New South Wales, Neuroscience Research Australia</p> <p>Chow, Jessica; University of New South Wales, Neuroscience Research Australia</p> <p>Miles, Lillian; University of New South Wales, Neuroscience Research Australia</p> <p>McInerney, Garth; University of New South Wales, Neuroscience Research Australia</p> <p>Toson, Barbara; University of New South Wales, Neuroscience Research Australia; Flinders University College of Medicine and Public Health</p> <p>Briggs, Nancy; University of New South Wales, Stats Central, Mark Wainwright Analytical Centre</p> <p>van Schooten, Kimberley; University of New South Wales, Neuroscience Research Australia; University of New South Wales, School of Population Health</p>
Keywords:	accidental falls, balance control, ageing, exercise, ehealth, aged, 65 and over

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts

1
2
3 1 **E-HEALTH “STANDINGTALL” BALANCE EXERCISE FOR FALL PREVENTION**
4 2 **IN OLDER PEOPLE: RESULTS OF A TWO-YEAR RANDOMISED CONTROLLED**
5 3 **TRIAL**
6 4

7 5 Kim Delbaere (0000-0002-5655-0234), Trinidad Valenzuela, Stephen R. Lord (0000-0002-
8 6 7111-8802), Lindy Clemson (0000-0003-2687-1114), G.A. Rixt Zijlstra, Jacqueline C.T.
9 7 Close, Thomas Lung (0000-0001-9978-6311), Ashley Woodbury, Jessica Chow, Garth
10 8 McInerney, Lillian Miles, Barbara Toson (0000-0001-6661-9971), Nancy Briggs (0000-0002-
11 9 1134-0807), Kimberley S. van Schooten (0000-0003-0902-8440)
12
13

14 10
15 11 Kim Delbaere

16 12 Associate Professor

17 13 Falls, Balance and Injury Research Centre, Neuroscience Research Australia, Randwick, 2031,
18 14 Australia. School of Population Health, University of New South Wales, Kensington, 2052,
19 15 Australia
20 16

21 17 Trinidad Valenzuela

22 18 Postdoctoral Research Associate

23 19 Physical Activity, Lifestyle, Ageing and Wellbeing Faculty Research Group, Faculty of
24 20 Medicine and Health, The University of Sydney, Sydney, 2006, Australia. Exercise Science
25 21 Laboratory, School of Kinesiology, Faculty of Medicine, Universidad Finis Terrae, Santiago,
26 22 7501015, Chile
27 23

28 24 Stephen R. Lord

29 25 Professor

30 26 Falls, Balance and Injury Research Centre, Neuroscience Research Australia, Randwick, 2031,
31 27 Australia. School of Population Health, University of New South Wales, Kensington, 2052,
32 28 Australia
33 29

34 30 Lindy Clemson

35 31 Professor

36 32 Faculty of Medicine & Health, The University of Sydney, Sydney, 2006, Australia
37 33

38 34 G.A. Rixt Zijlstra

39 35 Professor

40 36 Care and Public Health Research Institute, Department of Health Services Research, Maastricht
41 37 University, Maastricht, 6229GT, The Netherlands
42 38

43 39 Jacqueline C.T. Close

44 40 Professor

45 41 Falls, Balance and Injury Research Centre, Neuroscience Research Australia, Randwick, 2031,
46 42 Australia. Prince of Wales Hospital Clinical School, University of New South Wales,
47 43 Kensington, 2052, Australia
48 44

49 45 Thomas Lung

50 46 Senior Research Fellow

51 47 The George Institute for Global Health, University of New South Wales, Newtown, 2042,
52 48 Australia. Faculty of Medicine and Health, School of Public Health, The University of Sydney,
53 49 Sydney, 2006, Australia
54 50
55 51
56 52
57 53
58 54
59 55
60 56

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

51 Ashley Woodbury
52 Research Assistant
53 Falls, Balance and Injury Research Centre, Neuroscience Research Australia, Randwick, 2031,
54 Australia.
55
56 Jessica Chow
57 Research Assistant
58 Falls, Balance and Injury Research Centre, Neuroscience Research Australia, Randwick, 2031,
59 Australia.
60
61 Garth McInerney
62 Research Assistant
63 Falls, Balance and Injury Research Centre, Neuroscience Research Australia, Randwick, 2031,
64 Australia.
65
66 Lillian Miles
67 Research Assistant
68 Falls, Balance and Injury Research Centre, Neuroscience Research Australia, Randwick, 2031,
69 Australia.
70
71 Barbara Toson
72 Senior Research Fellow
73 Falls, Balance and Injury Research Centre, Neuroscience Research Australia, Randwick, 2031,
74 Australia. College of Medicine and Public Health, Flinders University, Adelaide, 5042,
75 Australia
76
77 Nancy Briggs
78 Senior Statistical Consultant
79 Stats Central, Mark Wainwright Analytical Centre, University of New South Wales,
80 Kensington, 2052, Australia
81
82 Kimberley S. van Schooten
83 Postdoctoral Fellow
84 Falls, Balance and Injury Research Centre, Neuroscience Research Australia, Randwick, 2031,
85 Australia. School of Population Health, University of New South Wales, Kensington, 2052,
86 Australia
87
88 Correspondence to: Kim Delbaere k.delbaere@neura.edu.au

1
2
3 89 **SUMMARY**
4

5 90 **Objectives:** The frequency and costs of falls result in an increasing need for effective, self-
6
7
8 91 managed fall prevention programmes for older people. The objective of this study was to test
9
10 92 whether *StandingTall*, an unsupervised, home-based, e-Health balance exercise programme
11
12 93 delivered via an App, could fill this void and prevent falls in community-dwelling older people.

13
14 94 **Design:** Assessor-blinded randomised controlled trial

15
16
17 95 **Setting:** Older people living independently in the community

18
19 96 **Participants:** 503 individuals aged 70+ who were independent in activities of daily living,
20
21 97 without cognitive impairment, progressive neurological disease or any other unstable or acute
22
23 98 medical condition precluding exercise.

24
25
26 99 **Interventions:** Participants were block randomised to an intervention group (IG: 2 hours of
27
28 100 *StandingTall* per week + health education; N=254) or a control group (CG: health education;
29
30 101 N=249) for 2-years.

31
32
33 102 **Main outcome measures:** The primary outcomes were rate of falls and number of fallers over
34
35 103 12-months. Secondary outcomes included falls, injurious falls, adherence, mood, health-related
36
37 104 quality of life and activity levels over 2-years, and balance and mobility outcomes over 12-
38
39 105 months.

40
41
42 106 **Results:** Both groups had a similar rate of falls and proportion of fallers at 12-months ($p=0.071$
43
44 107 and $p=0.461$ respectively). The IG had a 16% lower rate of falls over 2-years compared to CG
45
46 108 (incidence rate ratio:0.84, 95% confidence interval, 95%CI:0.72-0.98, $p=0.027$). Both groups
47
48 109 had a similar proportion of fallers at 2-years ($p=0.239$), but the proportion of injurious fallers
49
50 110 at 2-years was 20% lower in IG compared to CG (relative risk:0.80, 95%CI:0.66-0.98,
51
52 111 $p=0.031$). In the IG, 68.1% and 52.0% of participants exercised up to 12-months and 2-years
53
54 112 for a median of 114.0 (interquartile range, IQR:53.5) and 120.4 (IQR:38.6) weekly minutes
55
56 113 respectively. Groups remained similar in mood and activity levels. The IG had a 0.03
57
58
59
60

1
2
3 114 (95%CI:0.01-0.06) improvement on the EQ-5D-5L utility score at 6-months, and an
4
5 115 improvement in standing balance of 11-seconds (95%CI:2-19) at 6-months and 10-seconds
6
7
8 116 (95%CI:1-19) at 12-months. No serious training-related adverse events occurred.
9

10 117 **Conclusions:** *StandingTall* balance exercise did not significantly affect our primary outcomes.
11
12 118 It did significantly reduce the rate of falls and number of injurious fallers over 2-years. e-Health
13
14 119 exercise programmes may be a promising scalable fall prevention strategy.
15

16
17 120 **Trial registration:** ACTRN12615000138583
18

19 121 **Funding:** Australian National Health and Medical Research Council, Philanthropy.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 122 **WHAT IS KNOWN (2-3 sentences)**
4

- 5 123 • Balance exercise programmes are amongst the most effective fall prevention strategies,
6
7 with fall reduction rates of 23% in older community-dwelling people.
8 124
9
10 125 • Despite strong evidence that falls can be prevented, sustained full adherence in effective
11
12 trials is poor with pooled adherence rates of 21% (range 0-68%) at 12-months.
13 126
14
15 127 • Previous studies have shown that e-Health technology can offer a well-accepted method
16
17 for delivering unsupervised balance exercise to older people, with good adherence rates.
18 128
19

20 129

21
22 130 **WHAT THIS STUDY ADDS (1-2 sentences)**
23

- 24 131 • This study is the first large, long-term, and methodologically robust trial to examine
25
26 unsupervised technology-driven exercise as a strategy to prevent falls in older people.
27 132
28
29 133 • The *StandingTall* programme did not significantly affect rate of falls and proportion of
30
31 fallers at 1-year; however, *StandingTall* did significantly reduce the rate of falls and number
32
33 of injurious fallers over 2-years with a dose adherence of 30 to 40%.
34 135
35

36 136
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

137 INTRODUCTION

138 Falls and fall-related injuries have persisted over the past three decades as a leading cause of
139 morbidity and mortality in older people(1). With a rapidly ageing population globally,
140 sustainable access to evidence-based cost-effective fall prevention programmes is a priority.
141 High-quality systematic review and meta-regression evidence has confirmed that well-
142 designed exercise programmes are amongst the most effective fall prevention strategies for
143 community-dwelling older people, with fall reduction rates averaging 23%(2). However, to
144 achieve similar effectiveness at a population level, we need a programme that people can access
145 easily and adhere to long-term. Previous studies have found that older people prefer home-
146 based exercises and that the inclusion of balance exercises is associated with higher
147 adherence(3). Nevertheless, sustained adherence to prescribed home exercise programmes is
148 low with pooled estimates of 21% (range 0-68%)(4). Studies providing a physiotherapist-led
149 programme and/or a moderate level of home visits (i.e. <1 home visit per month and >2 home
150 visits in total) achieve higher levels of adherence(4), however, this substantially increases the
151 cost and reduces the feasibility as a population approach.

152
153 Digital technology can provide engaging and widely accessible methods for delivery of
154 exercise programmes to enhance long-term motivation and adherence at relatively low cost(5).
155 However, the provision of a well-designed unsupervised exercise programme, that is tailored
156 and progressive in nature, yet safe, could be a challenge. *StandingTall* is a unsupervised, home-
157 based e-Health balance exercise programme provided via an App, developed using principles
158 of consumer design to ensure an appropriate and user-friendly interface for older people.
159 Behavioural change strategies are incorporated to enhance exercise uptake and long-term
160 adherence(6).

161

1
2
3 162 This randomised controlled trial aimed to determine the effect of *StandingTall* on the
4
5 163 recommended set of core outcomes for fall prevention trials in older people (i.e. fall rate,
6
7 164 number of fallers and injurious fallers, and known fall risk factors including balance, gait,
8
9 165 concern about falling, health-related quality of life and physical activity levels)(7) over a 24-
10
11 166 month follow-up period, when compared with a health promotion education ‘control’
12
13 167 programme.
14
15
16
17
18
19
20
21

22 170 **METHODS**

23 171 **Study design**

24
25
26 172 We conducted a prospective, assessor-blinded, two-arm parallel randomised controlled trial
27
28 173 with 2-year follow-up in Sydney, Australia. The trial was approved by the UNSW Ethics
29
30 174 Committee in December 2014 (HC#14/266). It was registered prospectively in the Australian
31
32 175 and New Zealand Clinical Trials Registry (ACTRN12615000138583) on 13 February 2015
33
34 176 and the study protocol was published in 2015(6). The statistical analysis plan was preregistered
35
36 177 in October 2018 via the OpenScience framework (<https://osf.io/42gje/>) prior to completion of
37
38 178 data collection in November 2019. We used the CONSORT statement, ICMJE
39
40 179 recommendations and TiDieR checklist for preparation of this manuscript.
41
42
43
44
45
46

47 181 **Patient and Public Involvement**

48
49 182 *StandingTall* was developed using consumer design principles. A group of older people were
50
51 183 involved during the development of the *StandingTall* Application. They were asked to evaluate
52
53 184 an early version on its usability and age appropriateness as a means to engage in fall prevention
54
55 185 exercises using tablet-based technology. There was no other formal patient and public
56
57 186 involvement in this study.
58
59
60

187 **Participants**

188 We recruited community-living older people in the Sydney metropolitan area via flyers,
189 advertisements in local newspapers, presentations at residential and community senior centres,
190 and word of mouth. After initial screening by telephone, eligible individuals were invited to
191 participate if they were aged 70+ years, living in the community, independent in activities of
192 daily living, able to walk household distances without the use of a walking aid, and willing and
193 able to give informed consent and comply with the study protocol. Individuals were excluded
194 if they had an unstable or acute medical condition that precluded exercise participation,
195 suffered from a progressive neurological condition (such as Parkinson's disease, Multiple
196 Sclerosis), were cognitively impaired as defined by a Pfeiffer Short Portable Mental Status
197 Questionnaire (SPMSQ) score <8(9), or were currently participating in a fall prevention
198 programme. Eligibility was determined after informed verbal consent. Eligible individuals who
199 agreed to participate in the study were asked to provide informed written consent.

201 **Randomisation and masking**

202 Participants were randomised after completion of the baseline assessment. Permuted block
203 randomisation with mixed block lengths of four and six was applied to form two groups of
204 similar size (allocation ratio 1:1). People living in the same household were treated as one unit
205 to avoid contamination. Allocation was performed centrally using a web-based randomisation
206 programme by an investigator not involved in participant assessments or provision of the
207 intervention. Allocation concealment was ensured as the randomisation code was only released
208 after the baseline assessment was completed. Outcome assessors were blinded to study group
209 assignment throughout the trial. Statistical analyses were performed blinded for intervention or
210 control group allocation.

211

1
2
3 212 **Procedures**
4

5 213 All participants received a tablet computer with a health promotion education programme
6
7 214 which focused on health-related information relevant to older people, in addition to usual care,
8
9 215 for two years. This health promotion education programme comprised weekly fact sheets (104
10
11 216 in total) with information on healthy diet, medications, fall risk factors and exercise. The tablet-
12
13 217 based health education alone was chosen as the active control intervention to control for the
14
15 218 use of technology and allow data collection (i.e. falls during the trial period) through a tablet
16
17 219 computer for both groups.
18
19
20
21

22 220
23
24 221 The intervention group received the *StandingTall* programme, with exercise equipment (foam
25
26 222 cushion, stepping box, exercise mat), in addition to the health promotion education programme
27
28 223 and usual care. This intervention consisted of balance exercises delivered through a tablet
29
30 224 computer in the participants' homes with embedded behavioural change techniques, including
31
32 225 a weekly calendar for scheduling exercises, goal setting and educational fact sheets.
33
34 226 Participants were asked to exercise for at least two hours per week for the duration of the trial.
35
36 227 The intervention was introduced gradually; participants commenced with 40-minutes of
37
38 228 exercise per week, which was increased by 20-minutes fortnightly until participants reached
39
40 229 the required dose of 120-minutes per week in week 9. *StandingTall* delivers individually-
41
42 230 tailored balance exercises that increase in difficulty over time. It also allows people to choose
43
44 231 the time and duration of their exercise sessions. The intensity of the balance exercises is
45
46 232 monitored using a self-report modified rate of perceived exertion scale and is adjusted as
47
48 233 performance changes throughout the trial without the need of supervision. Exercise adherence
49
50 234 (volume, frequency) was monitored for 2-years following automatic data transfer to a server.
51
52 235 During the first 6-months, participants were encouraged to inform the research team when they
53
54 236 were going away or would not be able to exercise for a few weeks. Participants who did not
55
56
57
58
59
60

1
2
3 237 inform the team and did not reach 100-minutes for two consecutive weeks were contacted by
4
5 238 telephone to record the reason for non-adherence, discuss any issues related to the programme
6
7
8 239 and encourage adherence. These calls stopped after 6-months to gain a better understanding of
9
10 240 behavioural change and long-term exercise adherence.

11
12 241
13
14 242 Intervention group participants (IG) received two home visits. At the first visit, a qualified
15
16 243 exercise physiologist instructed the participant on how to use the *StandingTall* programme.
17
18 244 This occurred between 1 and 3-weeks after the baseline assessment and lasted approximately
19
20 245 1-hour. The second home visit of approximately 30-minutes at 1-month ensured safe use and
21
22 246 progression of training. Control group participants (CG) received two phone calls by qualified
23
24 247 exercise physiologists at the same time points, to discuss any issues with accessing the health
25
26 248 education programme and using additional features of the tablet computer.
27
28
29
30

31 249

32 33 250 **Outcomes**

34
35 251 The *primary outcome measures* were the rate of falls and proportion of fallers over the first 12-
36
37 252 months of the trial. A fall was defined as “an unexpected event in which the participant comes
38
39 253 to rest on the ground, floor or lower level”(7). Falls were monitored using prospective weekly
40
41 254 fall diaries through the tablet computer (over 24-months after baseline assessment). Fall
42
43 255 information was automatically uploaded to a database. Research staff contacted participants
44
45 256 with missing falls diaries by telephone at the end of each month to complete missing data. The
46
47 257 falls database was checked, reviewed and locked before group allocation was unmasked. Falls
48
49 258 that occurred up to 365-days (1-year) after randomisation were included in the primary
50
51 259 analysis. Falls that occurred up to 730-days (2-years) after randomisation were included as
52
53 260 secondary falls outcomes. Injurious falls were defined as falls resulting in any injury (e.g.
54
55
56
57
58
59
60

1
2
3 261 bruises, cuts/grazes, joint dislocations, sprains/strains, fractures, pain), or falls that required
4
5 262 medical care (e.g. visit to physician, emergency department).
6
7
8 263

9
10 264 *Secondary outcome measures* were assessed at baseline, at 6-months to examine acute effects,
11
12 265 and at 12, 18, and 24-months to examine retention effects. These measures included lab-based
13
14 266 balance and neuropsychological assessments (at baseline and at 6 and 12-months after baseline
15
16 267 assessment in the first 226 participants), and remote at-home measures of wellbeing, quality of
17
18 268 life and activity levels (at baseline and at 6, 12, 18, and 24-months after baseline assessment in
19
20 269 all participants). Physiological fall risk was assessed using the Physiological Profile
21
22 270 Assessment (PPA)(10). Balance, functional mobility and gait were assessed using tests of
23
24 271 standing balance (standing with feet in different positions for a maximum of 30-seconds per
25
26 272 condition: feet together, near-tandem, and tandem on floor and foam cushion and on left and
27
28 273 right foot on floor; sum of durations for all eight conditions), maximum forward-backward and
29
30 274 controlled leaning balance,(10) timed sit-to-stand(11), and up-and-go tests(12), short physical
31
32 275 performance battery(13), and self-selected walking speed over 10-meters(14). Stepping
33
34 276 performance was assessed with Choice, Stroop and Inhibitory Stepping Reaction Time tests
35
36 277 (15, 16). Cognitive function was assessed with the Montreal Cognitive Assessment(17), Trail-
37
38 278 Making Tests (TMT)(18), and the Victoria Stroop task(19). Psychological outcome measures
39
40 279 were assessed using by the iconographical Falls Efficacy Scale (concern about falling)(20),
41
42 280 nine-item Patient Health Questionnaire (mood)(21) and the COMPAS-W scale
43
44 281 (wellbeing)(22). Health-related quality of life was assessed using the 12-item WHO Disability
45
46 282 Assessment Schedule(23), 5-level EuroQol- 5 Dimension (EQ-5D-5L)(24), and 20-item
47
48 283 Assessment of Quality of Life 6-Dimensions (AQoL-6D) questionnaires(25). Detailed self-
49
50 284 report information on frequency and duration of physical activity was assessed using the
51
52 285 Incidental and Planned Exercise Questionnaire (IPEQ)(26). Daily-life activity was assessed
53
54
55
56
57
58
59
60

1
2
3 286 with the McRoberts MoveMonitor (McRoberts, the Netherlands) as the average duration of
4
5 287 daily walking and standing, and number of walking and standing bouts per day(27). A bout
6
7
8 288 was defined as a period of consecutive activity. Because participants were instructed to remove
9
10 289 the device before going to bed, we required a minimum wear duration of 12-hours per day on
11
12 290 one or more days for daily-life activity data to be included in the analysis. Daily-life activity
13
14 291 data were collected over a median of 6 (IQR 1) days for both groups.
15
16
17 292

18
19 293 *Process outcome measures* were captured as exercise duration via the tablet computer. Since
20
21 294 participants were allowed exercise breaks when they were sick or went on holiday, we averaged
22
23 295 weekly exercise duration as median values within individuals as a robust measure of central
24
25 296 tendency. We obtained subjective user experience by assessing usability, enjoyment and
26
27 297 exercise self-efficacy with the System Usability Scale (SUS)(28), Physical Activity Enjoyment
28
29 298 Scale (PACES)(29), Exercise Self-Efficacy Scale (ESES)(30), and Attitudes to Falls-Related
30
31 299 Interventions Scale (AFRIS)(31).
32
33
34
35 300

36
37 301 All outcome measures were assessed by trained exercise physiologists or physiotherapists
38
39 302 blinded to group allocation. Safety was assessed in terms of adverse events, which were defined
40
41 303 as any fall related to the prescribed exercise programme or involving the intervention
42
43 304 equipment.
44
45
46
47 305

48 49 306 **Statistical analysis**

50
51 307 *Sample size calculation.* Based on previous evidence, we carried out an a-priori sample size
52
53 308 calculation (5% significance level, 80% power, 33% effect, 20% dropout rate). This indicated
54
55 309 that a sample of 500 would be sufficient to evaluate the efficacy of the intervention on the rate
56
57
58
59
60

1
2
3 310 of falls and that a subsample of 200 would be sufficient to detect between-group differences in
4
5 311 physical outcome measure changes(6).
6
7
8 312

9
10 313 *Analysis plan.* Analyses were conducted according to the pre-defined statistical analysis plan,
11
12 314 as registered on the Open Science Framework (osf.io/42gje/). Data were coded to maintain
13
14 315 group allocation blinding during analysis. Effectiveness analyses of the primary outcome were
15
16 316 conducted on an intention-to-treat basis by a statistician (BT/NB) and independently replicated
17
18 317 by one of the investigators (KSvS). The alpha level was set to 5%. Analyses were performed
19
20 318 with Stata (version 16, Stata Corp.) and SPSS (version 25, IBM Corp.).
21
22
23 319

24
25 320 *Missing data.* In line with intention-to-treat principles, participants who were randomly
26
27 321 assigned to a group were included in the analysis irrespective to their level of compliance with
28
29 322 their group assignment. The primary outcome measures (i.e. number of falls per person-year
30
31 323 and proportion of fallers over 12-months) were analysed without imputation or adjustment for
32
33 324 descriptive characteristics, and with correction for follow-up duration when appropriate. The
34
35 325 faller status of people with incomplete follow up (n=66 at 12-months and n=188 at 24-months)
36
37 326 was assumed to be maintained during censoring. We used Little's MCAR test to determine the
38
39 327 missing data patterns of secondary outcome measures. The secondary outcome measures were
40
41 328 imputed using estimated means single imputation if they were Missing Completely At Random
42
43 329 (MCAR), or under the assumption of Missing At Random (MAR) using multiple imputation
44
45 330 to create 20 imputation datasets under joint multivariate normal imputation if they were not
46
47 331 MCAR. Psychological wellbeing, health-related quality of life and physical activity
48
49 332 questionnaire data were missing for 58 out of a total of 503 people at 6-months, for 82 people
50
51 333 at 12-months, for 98 at 18-months and for 99 people at 24-months. Daily-life activity
52
53 334 monitoring data was unavailable for 21 at baseline, 101 people at 6-months, 138 people at 12-
54
55
56
57
58
59
60

1
2
3 335 months, 148 people at 18-months and 156 people at 24-months. Clinic-based balance and
4
5 336 neuropsychological assessment data were missing for 42 people at 6-months, and for 47 people
6
7 337 at 12-months. These data were missing because of dropout, scheduling issues, non-adherence
8
9
10 338 or technical problems. Little's MCAR test indicated that all data were missing at random with
11
12 339 respect to participant baseline characteristics.

13
14 340

15
16
17 341 *Primary outcomes.* Primary outcomes were: (i) the number of falls per person-year, and (ii) the
18
19 342 proportion of fallers over 12-months. The number of falls per person-year was analysed using
20
21 343 Poisson regression to estimate the difference in fall rates between the two groups. The
22
23 344 incidence rate ratio and its 95% confidence interval (95%CI) are reported. Poisson regression
24
25 345 was selected over negative binomial regression (as a-priori registered in our statistical analysis
26
27 346 plan) to allow for a direct comparison to our planned complier average causal effects analysis
28
29 347 since the latter was based on a Poisson model. The results for the negative binomial regression
30
31 348 can be found in *Appendix 1*. Days of follow-up was included as an exposure term in these
32
33 349 models, i.e. the natural logarithm of the days of follow-up was added as an offset. The
34
35 350 proportion of fallers in the two groups was examined using modified Poisson regression models
36
37 351 for binary outcomes. Faller status was compared using: 0 falls versus 1+ falls; and relative risks
38
39 352 and their 95% CIs are reported.

40
41 353

42
43
44
45
46 354 *Secondary outcomes.* Secondary fall outcomes were the number of falls, the complier averaged
47
48 355 causal effect, proportion of fallers, and proportion of injurious fallers at 2-years. We employed
49
50 356 instrumental variable regression to correct for imperfect participant adherence and gain insight
51
52 357 into efficacy by estimating the complier averaged causal effect (CACE). We used a 2000-times
53
54 358 bootstrapped 2-stage CACE estimator comprised of a linear regression with adherence as the
55
56 359 dependent variable and group as the independent variable to obtain an estimate for adherence,
57
58
59
60

1
2
3 360 followed by a robust Poisson regression with falls as the dependent variable, the natural
4
5 361 logarithm of follow up in days as exposure, to estimate the effect of the intervention among
6
7 362 people with perfect adherence. The number of injurious falls per person-year was analysed
8
9 363 using Poisson regression to estimate the difference in injurious fall rates between the two
10
11 364 groups. We analysed secondary non-fall outcome measures with robust generalised linear
12
13 365 models using an exchangeable working correlation matrix and compared the change in scores
14
15 366 over time at 6, 12, 18 and 24-months between IG and CG. When the residuals of the generalised
16
17 367 linear models deviated from normality, we used a 1000-times bootstrap for each imputation
18
19 368 dataset to obtain confidence intervals.
20
21
22
23
24
25
26
27

28 371 **RESULTS**

29
30 372 Between February 2015 and October 2017, 823 individuals were screened (*Figure 1*). Five
31
32 373 hundred three people were included in the study and randomly assigned to IG (n=254) or CG
33
34 374 (n=249). We lost 90 participants during the 2-year follow-up (n=53 in IG and n=37 in CG) and
35
36 375 46 IG participants discontinued the intervention but kept contributing data. Baseline
37
38 376 characteristics of all participants are provided in *Table 1*.
39
40
41
42
43
44

45 378 **Effect on primary fall outcomes**

46
47 379 *Rate of falls at 12-months.* The average rate of falls over the first 12-months was 0.60 (SD
48
49 380 1.05) falls per year in IG and 0.76 (SD 1.25) in CG. The difference in fall rate was not
50
51 381 statistically different, with an incidence rate ratio (IRR) of 0.82 (95% confidence interval; 95%
52
53 382 CI 0.66-1.02), $p=0.071$, in IG compared to CG (see *Figure 2*).
54
55
56
57
58
59
60

1
2
3 384 *Proportion of fallers at 12-months.* Overall, 188 participants (37.4%) fell at least once in the
4
5 385 12-month follow-up. IG and CG participants were equally likely to fall at least once, with a
6
7 386 relative risk of 0.90 (95% CI 0.67-1.20), $p=0.461$, in the IG compared to the CG.
8
9

10 387

11
12 388 **Effect on secondary fall outcomes**

13
14 389 *Rate of falls at 24-months.* The average rate of falls over the two-year follow-up was 0.57 (SD
15
16 0.95) falls per year in IG and 0.72 (SD 1.17) in CG. The difference in fall rate was statistically
17
18 390 different, with an IRR of 0.84 (95% CI 0.72-0.98), $p=0.027$, in IG compared to CG.
19
20 391

21 392

22
23 393 *Rate of falls via complier averaged causal effects at 24-months.* CACE analysis revealed an
24
25 394 IRR of 0.72 (95% CI 0.21-1.13), $p=0.324$, in IG compared to CG. This IRR was similar to that
26
27 395 of the intention-to-treat analysis.
28
29

30 396

31
32 397 *Proportion of fallers at 24-months.* 270 participants (53.7%) fell at least once in the 24-month
33
34 398 follow-up. IG and CG participants were equally likely to fall at least once, with a relative risk
35
36 399 of 0.87 (95% CI 0.68-1.10), $p=0.239$, in the IG compared to the CG.
37
38

39 400

40
41 401 *Proportion of injurious fallers at 24-months.* 210 participants (41.7%) experienced an injurious
42
43 402 fall during the 24-month follow-up. IG participants were less likely to be injurious fallers than
44
45 403 CG participants, with a relative risk of 0.80 (95% CI 0.66-0.98), $p=0.031$.
46
47 404

48
49 405

50
51 405 **Effect on secondary outcomes on wellbeing, quality of life and activity levels**

52
53 406 We found no significant difference in psychological wellbeing or physical activity levels at 6,
54
55 407 12, 18 and 24-months in IG compared to CG (*Table 2*). We did find a small improvement of
56
57 408 0.03 (95% CI 0.01-0.06) on the EQ-5D-5L utility score at 6-months in IG compared to CG. All
58
59
60

1
2
3 409 other health-related quality of life measures showed no difference between IG and CG groups
4
5 410 at all time points.
6
7
8 411

412 **Effect on secondary outcomes of balance and neuropsychological assessments**

413 The 226 participants (45% of the total sample; 114 IG and 112 CG) who were invited for
414 laboratory re-assessments were on average 1.1 years older (78.0 years (SD 5.4) vs 76.9 years
415 (5.5) in those not invited; $t(501)=-2.294$, $p=0.022$) and scored 0.40 points higher on
416 physiological fall risk (measured with PPA (1.10 (SD 0.82) vs 0.70 (0.90) in those not invited;
417 $t(501)=-5.063$, $p<0.001$). There were no other significant differences in baseline characteristics
418 between these groups. We observed a significant improvement in standing balance at 6 and 12-
419 months (11-seconds, 95%CI 3-19 and 10-seconds, 95%CI 1-19, respectively) in IG compared
420 to CG (*Table 3*). We found no significant difference in physiological fall risk, maximum
421 forward-backward and controlled leaning balance, functional mobility and gait tests, stepping
422 performance, or cognitive and executive functions at 6 or 12-months in IG compared to CG.

423

424 **Subgroup analyses**

425 Planned subgroup analyses in participants who did or did not experience falls in the past 12-
426 months or had low or high physiological fall risk, concern about falling or executive function
427 scores (median splits on PPA, Icon-FES and TMT-B) at baseline suggested no mediation on
428 rate of falls (all $p\geq 0.058$; see Appendix 2). The subgroup analysis did suggest mediation by
429 baseline status of physiological fall risk on physiological fall risk and by baseline status of
430 concern about falling on concern about falling ($p=0.004$ and $p=0.027$ resp.; see Appendix 3).
431 People with lower physiological fall risk at baseline had a significantly greater improvement
432 of physiological fall risk at 6 months of 0.52 (95% CI 0.17-0.88) points. People with higher

1
2
3 433 concern about falling at baseline had a significantly lower improvement of concern about
4
5 434 falling at 12 months of -5 (95% CI -9, -1) points.
6
7
8 435

9
10 436 **Process outcomes**

11
12 437 *Adverse events.* Five falls occurred in three IG participants while exercising, which led to minor
13
14 438 injuries (grazes, bruising, cuts). These falls were directly related to the intervention. Three falls
15
16 439 occurred during exercise sessions and two were due to trips over exercise equipment.
17
18
19 440

20
21 441 *Adherence.* A total of 51 IG participants (20.1%) at 6-months, 81 (31.9%) at 12-months, 104
22
23 442 (40.9%) at 18-months, and 122 (48.0%) at 2-years had a median adherence of 0-minutes per
24
25 443 week, either because of drop-out or non-usage attrition (see *Figure 1*). The remaining
26
27 444 participants exercised for a median of 105.0 (IQR 58.5, n=203) minutes per week over the first
28
29 445 6-months, 114.0 (IQR 53.5, n=173) minutes per week over the first 12-months, 120.0 (IQR
30
31 446 39.3, n=150) minutes per week over 18-months and 120.3 (IQR 38.6, n=132) minutes per week
32
33 447 over the full 2-years. Overall, 40.0%, 34.1%, 33.1% and 29.8% of IG participants achieved the
34
35 448 prescribed dose over 6-, 12-, 18- and 24-months respectively.
36
37
38 449

39
40
41 450 *Attitudes and usability.* AFRIS and ESES scores at baseline were similar for both groups
42
43 451 ($p=0.595$ and $p=0.681$ respectively) with medians of 42 (IQR 9) and 86 (IQR 22) in CG vs. 42
44
45 452 (IQR 8) and 87 (IQR 23) in IG. We repeated AFRIS and ESES and obtained PACES and SUS
46
47 453 in IG at 6, 12, 18 and 24-months. AFRIS declined over time ($p<0.0001$) from a median of 42
48
49 454 (IQR 8) at baseline, to 40 (IQR 10) at 6-months, 39 (IQR 11) at 12-months, 39 (IQR 14) at 18-
50
51 455 months and 35 (IQR 18) at 24-months, suggesting reduced intentions to continue the
52
53 456 intervention. ESES also declined over time ($p<0.0001$) from a median of 87 (IQR 23) at
54
55 457 baseline, to 75 (IQR 28) at 6-months, 70 (IQR 27) at 12-months, 69 (IQR 39) at 18-months and
56
57
58
59
60

1
2
3 458 59 (IQR 41) at 24-months, suggesting reduced exercise self-efficacy. PACES and SUS
4
5 459 remained stable over time ($p=0.362$ and $p=0.697$ respectively) with medians of 27 (IQR 14)
6
7 460 and 4.4 (IQR 0.8).
8
9

10 461

11
12 462

13 14 463 **DISCUSSION**

15
16
17 464 To our knowledge, this is the first large randomised controlled trial to evaluate the effects of a
18
19 465 digital, unsupervised balance exercise programme on falls. We observed no significant effects
20
21 466 on our primary outcomes, rate of falls and proportion of fallers, at 12-months. Yet, we did
22
23 467 observe a significant reduction in fall rate of 16% and in proportion of injurious fallers of 20%
24
25 468 at 24-months. Moreover, albeit not statistically significant ($p=0.07$), the effect size of a 18%
26
27 469 reduction of fall rate at 12-months was similar to that at 24-months. The observed reduction in
28
29 470 fall rate is comparable to that of previous studies, which achieved a 21% reduction with
30
31 471 individually-delivered exercise programmes over 12-months and 14% over 24-months(2, 28).
32
33 472 The 20% reduction in the proportion of injurious fallers at 24-months, on the other hand, may
34
35 473 be higher than the previously reported 12% reductions(33). These findings indicate that
36
37 474 technology can be used to deliver an e-Health balance exercise programme to older people
38
39 475 which is effective at reducing fall rates and the proportion of injurious fallers over 24-months.
40
41
42
43
44

45 476

46
47 477 Secondary outcome analyses were not able to clearly highlight the pathway through which the
48
49 478 reduction in falls rate and injurious fallers was achieved. In a subgroup of 226 participants, we
50
51 479 observed a significant improvement in standing balance at 6 and 12-months; however, this was
52
53 480 not confirmed through other balance and functional mobility measures. The *StandingTall* app
54
55 481 includes a monthly balance assessment that comprises maintaining standing posture with feet
56
57 482 in different positions, it is possible that the repeated practice carried over to laboratory
58
59
60

1
2
3 483 assessments for IG participants. This trial might have been underpowered for detecting
4
5 484 differences in fall risk factors, as our sample had a lower fall risk than anticipated. The a-priori
6
7 485 sample size calculation was based on a sample with a mean physiological fall risk score (PPA)
8
9 486 of 1.9 (SD 1.1) which is a full point higher than that of the current sample (PPA of 0.88, SD
10
11 487 0.88)(6). Interestingly, our pre-registered subgroup analyses found no significant modification
12
13 488 of falls but did find indications of significant modification of the assessment outcomes, in
14
15 489 people with lower physiological fall risk and lower concern about falling benefitting more.
16
17 490 Quality of life measured with the EQ-5D-5L utility index also showed a significant
18
19 491 improvement at 6-months, however no significant differences were found at 12 or 24-months.
20
21
22 492
23
24
25 493 Adherence to the intervention was good compared to previous exercise trials, with 40% of
26
27 494 participants being fully adherent over the first 6-months and 30% being fully adherent over the
28
29 495 full 2-years compared to pooled estimates of 21% in previous trials(31). Eighty percent of IG
30
31 496 participants had a median adherence of 105-minutes over 6-months, and over half sustained a
32
33 497 median adherence of 120-minutes over 24-months, despite the low level of contact during the
34
35 498 study (two home visits in the first month and incidental follow-up calls to complete missing
36
37 499 data). Adherence was collected automatically and is therefore a true representation of the actual
38
39 500 dosage of balance training people received. Enjoyment and usability of the *StandingTall*
40
41 501 intervention remained high throughout the entire study duration. Weekly medians suggest that
42
43 502 the exercises might have become part of the lifestyle of those participants who remained in the
44
45 503 study. While intentions and self-efficacy towards completing 2-hours of exercise per week
46
47 504 declined over time, this is likely a more realistic reflection of actual long-term self-efficacy.
48
49 505 The high adherence and zero serious adverse events support the feasibility and safety of
50
51 506 upscaling the intervention to a population level.
52
53
54
55
56
57
58
59
60

1
2
3 508 The strengths of this study were its large sample size, pragmatic design using a programme that
4
5 509 could be delivered as part of routine care, broad inclusion criteria and use of methods designed
6
7 510 to reduce the risk of bias such as concealed random allocation to groups, blinded outcome
8
9 511 assessment, intention-to-treat analyses, and pre-registered statistical analysis plan (see PEDRO
10
11 512 assessment in *Appendix 4*). The primary study limitations were the reliance on self-reported
12
13 513 falls; however, the weekly e-diaries by both groups should have removed a reporting bias.
14
15 514 Similar to many other exercise trials, participant masking was not possible. This might have
16
17 515 led to bias by expectation, considering that many outcomes were self-rated. Thirdly, our study
18
19 516 design intentionally included more than one outcome measure to account for the complex
20
21 517 aetiology of falls, and, in theory, the subsequent multiple testing of the results could introduce
22
23 518 error. Finally, it is possible that our weekly education fact sheets have induced a behaviour
24
25 519 change in our control group, reducing our statistical power.
26
27
28
29
30

31 520
32
33 521 Novel methods for delivery of quality healthcare are required to increase effectiveness of fall
34
35 522 prevention programs while containing costs and using scarce human resources to maximum
36
37 523 effect. The ultimate success of a health promotion programme depends both on its effectiveness
38
39 524 and its reach and acceptability in the community. A recently published multifactorial fall
40
41 525 prevention trial in 5,451 older people at high risk of fall injuries illustrated that all participants
42
43 526 had poor balance, and 95% agreed to take up an exercise program (30). Yet, the authors
44
45 527 indicated that uptake and adherence to community-based exercise programs was low, and the
46
47 528 evidence-base of these available exercise programs was uncertain (30). *StandingTall* fills an
48
49 529 important gap by assisting older people to exercise at home, i.e. those who are unable (or
50
51 530 unwilling) to attend out-of-house or group exercises, or those who wish to combine group and
52
53 531 home-based exercises. Also, in light of the COVID-19 pandemic, as face-to-face delivery has
54
55 532 been curtailed and de-conditioning is widespread, e-Health can offer an engaging, home-based
56
57
58
59
60

1
2
3 533 substitute to reduce long-term adverse health consequences in older people from extended
4
5 534 periods of isolation. E-Health programmes such as *StandingTall* can provide older people with
6
7
8 535 an opportunity to stay active to prevent physical deconditioning and concomitant falls,
9
10 536 functional dependence and increased healthcare use while maintaining COVID-19 safety
11
12 537 recommendations.

13
14
15 538

16
17 539 In conclusion, our results show that a tailored e-Health exercise programme is an effective,
18
19 540 low-resources, and thus low-cost, intervention towards the prevention of falls in older people.
20
21 541 *StandingTall* is a scalable intervention and can be easily implemented into clinical practice,
22
23 542 providing health professionals with a platform to remotely set-up, monitor and tailor the
24
25 543 programme for their patients. *StandingTall* offers full user autonomy and requires minimal
26
27 544 interaction with health professionals. An economic evaluation is planned to be undertaken to
28
29 545 determine whether *StandingTall* represents value for money.

30
31
32
33 546
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Contributor and guarantor information

Conceptualisation, KD, SRL, LC, GARZ, JCTC, BT; data collection, KD, TV, AW, JC, GM, LM, KSvS; data analysis, BT, NB, KSvS; data interpretation: KD, TL, KSvS; writing—original draft preparation, KD, KSvS; writing—review and editing, TV, SRL, LC, GARZ, JCTC, TL, AW, JC, GM, LM, BT, NB; final approval, KD, TV, SRL, LC, GARZ, JCTC, TL, AW, JC, GM, LM, BT, NB, KSvS, guarantor: KD. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Data sharing

Deidentified participant data may be accessed by researchers who provide a methodologically sound proposal. Proposals should be directed to k.delbaere@neura.edu.au and data are available from the date of publication of this manuscript. The study protocol is available as a free-access publication(6) and the statistical analysis plan is available on OpenScience framework (<https://osf.io/42gje/>).

Transparency statement

Kim Delbaere (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned (and, if relevant, registered) have been explained.

Declaration of interests

The authors reported that the PPA (NeuRA FallScreen) is commercially available through Neuroscience Research Australia. No other conflicts of interest were reported.

Role of the funding source

This study was funded by Australian National Health and Medical Research Council grant APP1084739, Gandel Philantropy and NeuRA Foundation. KD and SRL were supported by the Australian National Health and Medical Research Council (APP1105106, APP1117171). TL is currently supported by a NHMRC Early Career Fellowship (APP1141392) and National Heart Foundation Postdoctoral Fellowship (award ID 101956). KSvS was supported by a Human Frontier Science Program Fellowship (LT001080/2017). The funders did not have a role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Copyright/license for publication

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors upon acceptance of this article for publication by the Publishers, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.

593 **REFERENCES**

- 594 1. James SL, Lucchesi LR, Bisignano C, Castle CD, Dingels ZV, Fox JT, et al. The global
595 burden of falls: global, regional and national estimates of morbidity and mortality from the
596 Global Burden of Disease Study 2017. *Injury Prevention*. 2020;injuryprev-2019-043286.
- 597 2. Sherrington C, Fairhall NJ, Wallbank GK, Tiedemann A, Michaleff ZA, Howard K, et al.
598 Exercise for preventing falls in older people living in the community. *Cochrane Database*
599 *of Systematic Reviews*. 2019(1).
- 600 3. Yardley L, Donovan-Hall M, Francis K, Todd C. Attitudes and beliefs that predict older
601 people's intention to undertake strength and balance training. *The Journals of Gerontology*
602 *Series B: Psychological Sciences and Social Sciences*. 2007;62(2):P119-P25.
- 603 4. Simek EM, McPhate L, Haines TP. Adherence to and efficacy of home exercise programs
604 to prevent falls: A systematic review and meta-analysis of the impact of exercise program
605 characteristics. *Preventive Medicine*. 2012;55(4):262-75.
- 606 5. Lamb SE, Jorstad-Stein EC, Hauer K, Becker C, Prevention of Falls Network E, Outcomes
607 Consensus G. Development of a common outcome data set for fall injury prevention trials:
608 the Prevention of Falls Network Europe consensus. *J Am Geriatr Soc*. 2005;53(9):1618-
609 22.
- 610 6. Delbaere K, Valenzuela T, Woodbury A, Davies T, Yeong J, Steffens D, et al. Evaluating
611 the effectiveness of a home-based exercise programme delivered through a tablet computer
612 for preventing falls in older community-dwelling people over 2 years: study protocol for
613 the Standing Tall randomised controlled trial. *BMJ Open*. 2015;5(10):e009173.
- 614 7. Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain
615 deficit in elderly patients. *Journal of the American Geriatrics Society*. 1975;23(10):433-
616 41.
- 617 8. Lord SR, Menz HB, Tiedemann A. A physiological profile approach to falls risk
618 assessment and prevention. *Physical therapy*. 2003;83(3):237-52.
- 619 9. Csuka M, McCarty DJ. Simple method for measurement of lower extremity muscle
620 strength. *The American journal of medicine*. 1985;78(1):77-81.
- 621 10. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for
622 frail elderly persons. *Journal of the American geriatrics Society*. 1991;39(2):142-8.
- 623 11. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short
624 physical performance battery assessing lower extremity function: association with self-
625 reported disability and prediction of mortality and nursing home admission. *Journal of*
626 *gerontology*. 1994;49(2):M85-M94.
- 627 12. Bohannon RW. Comfortable and maximum walking speed of adults aged 20—79 years:
628 reference values and determinants. *Age and Ageing*. 1997;26(1):15-9.
- 629 13. Schoene D, Smith ST, Davies TA, Delbaere K, Lord SR. A Stroop Stepping Test (SST)
630 using low-cost computer game technology discriminates between older fallers and non-
631 fallers. *Age and Ageing*. 2014;43(2):285-9.
- 632 14. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The
633 Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive
634 impairment. *Journal of the American Geriatrics Society*. 2005;53(4):695-9.
- 635 15. Reitan RM, Wolfson D. The Halstead-Reitan neuropsychological test battery: Theory and
636 clinical interpretation. Tucson, Ariz: Neuropsychology Press.; 1985.
- 637 16. Trenerry MR, Crosson B, DeBoe J, Leber W. Stroop neuropsychological screening test.
638 Odessa, FL: Psychological Assessment Resources. 1989.
- 639 17. Delbaere K, T. Smith S, Lord SR. Development and Initial Validation of the
640 Iconographical Falls Efficacy Scale. *The Journals of Gerontology: Series A*.
641 2011;66A(6):674-80.

- 1
2
3 642 18. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity
4 643 measure. *Journal of general internal medicine*. 2001;16(9):606-13.
- 5 644 19. Gatt JM, Burton KL, Schofield PR, Bryant RA, Williams LM. The heritability of mental
6 645 health and wellbeing defined using COMPAS-W, a new composite measure of wellbeing.
7 646 *Psychiatry Research*. 2014;219(1):204-13.
- 8 647 20. Üstün TB, Chatterji S, Kostanjsek N, Rehm J, Kennedy C, Epping-Jordan J, et al.
9 648 Developing the World Health Organization disability assessment schedule 2.0. *Bulletin of*
10 649 *the World Health Organization*. 2010;88:815-23.
- 11 650 21. Viney R, Norman R, King MT, Cronin P, Street DJ, Knox S, et al. Time trade-off derived
12 651 EQ-5D weights for Australia. *Value in Health*. 2011;14(6):928-36.
- 13 652 22. Richardson JR, Peacock SJ, Hawthorne G, Iezzi A, Elsworth G, Day NA. Construction of
14 653 the descriptive system for the assessment of quality of life AQoL-6D utility instrument.
15 654 *Health and quality of life outcomes*. 2012;10(1):38.
- 16 655 23. Delbaere K, Hauer K, Lord SR. Evaluation of the incidental and planned activity
17 656 questionnaire for older people. *British journal of sports medicine*. 2010;44(14):1029-34.
- 18 657 24. van Schooten KS, Rispens SM, Elders PJ, Lips P, van Dieen JH, Pijnappels M. Assessing
19 658 physical activity in older adults: required days of trunk accelerometer measurements for
20 659 reliable estimation. *Journal of aging and physical activity*. 2015;23(1):9-17.
- 21 660 25. Bangor A, Kortum P, Miller J. Determining what individual SUS scores mean: Adding an
22 661 adjective rating scale. *Journal of usability studies*. 2009;4(3):114-23.
- 23 662 26. Kendzierski D, DeCarlo KJ. Physical activity enjoyment scale: Two validation studies.
24 663 *Journal of sport & exercise psychology*. 1991;13(1).
- 25 664 27. Everett B, Salamonsen Y, Davidson PM. Bandura's exercise self-efficacy scale: validation
26 665 in an Australian cardiac rehabilitation setting. *Int J Nurs Stud*. 2009;46(6):824-9.
- 27 666 28. Finnegan S, Seers K, Bruce J. Long-term follow-up of exercise interventions aimed at
28 667 preventing falls in older people living in the community: a systematic review and meta-
29 668 analysis. *Physiotherapy*. 2019;105(2):187-99.
- 30 669 29. Zhao R, Bu W, Chen X. The efficacy and safety of exercise for prevention of fall-related
31 670 injuries in older people with different health conditions, and differing intervention
32 671 protocols: a meta-analysis of randomized controlled trials. *BMC Geriatrics*.
33 672 2019;19(1):341.
- 34 673 30. Bhasin S, Gill TM, Reuben DB, Latham NK, Ganz DA, Greene EJ, et al. A Randomized
35 674 Trial of a Multifactorial Strategy to Prevent Serious Fall Injuries. *New England Journal of*
36 675 *Medicine*. 2020;383(2):129-40.
- 37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURES AND TABLES


Figure 1: Flowchart of study recruitment and retention.

Figure 2: Effect on rate of falls and faller status. Primary outcomes are bolded, values indicate incidence rate ratio (IRR) or relative risk (RR) with corresponding 95% confidence interval (95% CI). Vertical line indicates no difference between the groups (i.e. IRR or RR of 1). CACE shows complier average causal effect.




Table 1: Baseline characteristics of all participants (N=503)

Variable	Intervention (n=254)	Control (n=249)
Age (years)	77.1 (5.5)	77.7 (5.5)
Female gender (%)	177 (69.7%)	162 (65.1%)
BMI (kg/m ²)	27.3 (4.5)	27.0 (4.9)
Education (years)	14.4 (4.1)	14.6 (4.4)
Living alone (%)	113 (44.5%)	104 (41.9%)
Owens a computer (%)	214 (85.0%)	220 (88.4%)
Uses walking aid (%)	18 (7.1%)	20 (8.0%)
Falls in previous year (number)	0 [1]	0 [1]
EQ-5D-5L VAS (score range 0 - 100)	90 [15]	85 [15]
Medical conditions (number)	0 [1]	0 [1]
Prescription medication (number) [#]	3 [3]	3 [3]
Montreal Cognitive Assessment (score range 0 - 30)	27 [3]	27 [3]
Trail Making Test B minus A (TMT-B min TMT-A; seconds)	55.3 [36.2]	54.8 [44.8]
Patient Health Questionnaire (PHQ-9; score range 0 - 27)	2 [4]	2 [4]
Iconographical Falls Efficacy Scale (icon-FES; score range 30 - 120)	53 (16)	55 (16)
Physiological fall risk (PPA score)	0.99 (0.74)	1.19 (0.87)
Timed up and go (seconds)	8.5 (3.3)	8.6 (3.0)

Note: values are mean (standard deviation), absolute (relative %) or median [IQR]; end of range indicating best score is underlined.

[#]available for 335 (66.6%) of people.

Table 2: Effect on secondary outcome measures in all participants

Variable better scores underlined	Control group Mean (SD)					Intervention group Mean (SD)					Change in IG compared to CG Beta (95% confidence interval), p			
	0M	6M	12M	18M	24M	0M	6M	12M	18M	24M	0-6M	0-12M	0-18M	0-24M
Psychological wellbeing														
PHQ-9 (score range 0 - 27)	2 [4]	3 [5]	3 [4]	4 [3]	3 [5]	2 [4]	2 [4]	3 [4]	3 [5]	3 [4]	0 (0, 0), p=NA	0 (0, 0), p=NA	0 (0, 0), p=NA	0 (0, 0), p=NA
Icon-FES (score range 30 - 120)	55 (16)	53 (16)	55 (16)	57 (20)	58 (18)	53 (16)	52 (17)	51 (16)	52 (19)	53 (18)	2 (-2, 6) p=0.331	-1 (-5, 3) p=0.597	-2 (-6, 2) p=0.254	-2 (-6, 2) p=0.400
COMPAS-W (score range 26 - 130)	100 (11)	100 (11)	100 (11)	100 (12)	100 (11)	101 (12)	102 (12)	102 (12)	102 (13)	102 (12)	1 (-1, 4) p=0.342	1 (-1, 4) p=0.324	1 (-2, 3) p=0.614	1 (-1, 4) p=0.313
Health-related quality of life														
WHODAS (score range 0 - 100%)	6.3 [12.5]	7.2 [15.6]	8.8 [14.7]	8.1 [16.5]	6.3 [16.5]	4.1 [10.4]	4.9 [12.9]	6.3 [13.4]	6.2 [14.5]	7.7 [14.6]	-1.6 (-4.1, 0.8), p=NA	-0.2 (-2.7, 2.3), p=NA	0.3 (-2.5, 3.1), p=NA	0.2 (-2.0, 2.5), p=NA
EQ-5D-5L VAS (score range 0 - 100)	85 [15]	87 [16]	83 [19]	80 [16]	80 [20]	90 [15]	90 [14]	89 [11]	87 [15]	88 [14]	-2 (-6, 3), p=NA	0 (-4, 4), p=NA	-2 (-6, 2), p=NA	1 (-4, 6), p=NA
EQ-5D-5L utility (score range 0 - 1)	0.89 [0.03]	0.87 [0.04]	0.87 [0.05]	0.86 [0.06]	0.86 [0.05]	0.89 [0.04]	0.87 [0.05]	0.87 [0.05]	0.87 [0.06]	0.88 [0.05]	0.03 (0.01, 0.06), p=NA	-0.01 (-0.04, 0.03), p=NA	0.01 (-0.02, 0.05), p=NA	0.01 (-0.02, 0.04), p=NA
AQOL-6D (utility score range 0 - 1)	0.88 [0.16]	0.87 [0.15]	0.87 [0.16]	0.86 [0.20]	0.86 [0.16]	0.89 [0.14]	0.90 [0.15]	0.89 [0.16]	0.90 [0.19]	0.89 [0.15]	0.01 (-0.02, 0.04), p=NA	-0.01 (-0.04, 0.02), p=NA	0.14 (-0.94, 1.24), p=NA	0.01 (-0.02, 0.03), p=NA
Physical activity levels														
IPEQ planned activity (hrs)	5.3 [6.7]	5.0 [7.6]	4.9 [5.8]	4.2 [7.3]	4.4 [6.0]	5.4 [7.6]	5.7 [9.1]	5.9 [7.4]	5.0 [7.4]	5.0 [6.5]	0.5 (-0.8, 1.8), p=NA	0 (-4.3, 4.2), p=NA	-1.6 (-5.6, 2.4), p=NA	1.1 (-3.6, 5.7), p=NA
IPEQ incidental activity (hrs)	34.0 [28.9]	38.0 [30.1]	32.0 [33.6]	36.9 [24.3]	33.8 [35.4]	33.0 [35.2]	38.0 [32.9]	32.0 [33.8]	36.9 [24.4]	37.8 [34.6]	-2.8 (-7.8, 2.3), p=NA	-0.9 (-6.8, 5.0), p=NA	-1.7 (-7.0, 3.7), p=NA	-1.9 (-7.3, 3.4), p=NA

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

IPEQ planned exercise (hrs)	3.0 [4.9]	3.1 [4.7]	3.0 [4.5]	2.7 [4.5]	2.6 [3.9]	2.8 [4.9]	3.5 [5.3]	3.6 [4.9]	2.7 [4.4]	3.0 [4.7]	0.6 (-0.4, 1.7), p=NA	0.9 (-0.1, 2.0), p=NA	0.1 (-0.9, 1.2), p=NA	0.6 (-0.5-1.6), p=NA
MM Walking time (hrs)	1.26 (0.47)	1.20 (0.47)	1.16 (0.51)	1.13 (0.49)	1.19 (0.54)	1.35 (0.59)	1.31 (0.54)	1.25 (0.61)	1.21 (0.55)	1.21 (0.61)	0.02 (-0.11, 0.14) p=0.790	0.01 (-0.13, 0.14) p=0.901	-0.01 (-0.14, 0.12) p=0.875	-0.07 (-0.19, 0.06) p=0.301
MM Walking bouts	423 (142)	429 (153)	418 (163)	396 (161)	411 (175)	441 (162)	459 (182)	444 (179)	424 (171)	413 (184)	11 (-31, 54) p=0.583	8 (-34, 51) p=0.692	10 (-36, 56) p=0.644	-16 (-58, 27) p=0.452
MM Standing time (hrs)	2.52 (0.75)	2.55 (0.92)	2.52 (0.87)	2.42 (0.86)	2.44 (0.93)	2.59 (0.87)	2.65 (1.11)	2.62 (0.99)	2.48 (1.01)	2.34 (0.96)	0.03 (-0.23, 0.30) p=0.788	0.03 (-0.23, 0.28) p=0.825	-0.01 (-0.26, 0.23) p=0.913	-0.16 (-0.41, 0.09) p=0.190
MM Standing bouts	870 (289)	880 (314)	877 (312)	824 (297)	848 (353)	880 (320)	948 (366)	934 (361)	876 (355)	825 (355)	59 (-24, 142) p=0.156	47 (-38, 132) p=0.263	42 (-48, 132) p=0.338	-32 (-116, 52) p=0.433

Note: values are mean (standard deviation) or median [IQR]; end of range indicating best score is underlined; p=NA indicates bootstrapped outcomes, which did not allow us to estimate p-values.

PHQ-9: nine-item Patient Health Questionnaire; Icon-FES: Iconographical Falls Efficacy Scale; COMPAS-W: COMPAS-W scale; WHODAS: 12-item WHO Disability Assessment Schedule; EQ-5D-5L: 5-level EuroQol- 5 Dimension; AQOL-6D: 20-item Assessment of Quality of Life 6-Dimensions; IPEQ: Incidental and Planned Exercise Questionnaire; MM: McRoberts MoveMonitor.

Table 3: Effect on secondary outcome measures in a subsample of 226 participants

Variable	Control group Mean (SD)			Intervention group Mean (SD)			Change in intervention compared to control group Beta (95% CI), p	
	0M	6M	12M	0M	6M	12M	0-6M	0-12M
Physiological fall risk								
PPA score	1.19 (0.87)	1.17 (0.77)	0.97 (0.93)	0.99 (0.74)	0.82 (0.82)	0.76 (0.92)	-0.15 (- 0.39, 0.09) p=0.214	-0.01 (- 0.27, 0.26) p=0.955
Balance, functional mobility and gait								
Standing balance (s)	188 [69]	189 [81]	186 [73]	193 [95]	209 [71]	198 [70]	11 (3, 19), p=NA	10 (1, 19), p=NA
Maximum lean range AP (cm)	15 (3)	16 (4)	18 (4)	15 (3)	17 (4)	19 (4)	1 (0, 2) p=0.206	1 (0, 2) p=0.213
Coordinated lean (score)	7 [13]	9 [15]	8 [11]	7 [11]	6 [11]	5 [12]	-2 (-4, 0), p=NA	-1 (-3, 1), p=NA
Timed up and go (s)	8.6 (3.0)	8.7 (3.6)	8.6 (4.1)	8.5 (3.3)	8.5 (3.4)	8.2 (3.3)	-1.8 (-4.4, 0.7) p=0.146	-1.5 (-3.7, 0.8) p=0.190
5-times sit-to-stand (s)	12.4 (4.3)	12.1 (5.2)	11.5 (4.7)	12.4 (5.4)	12.1 (4.6)	11.0 (3.8)	0.1 (-1.0, 1.2) p=0.864	-0.4 (-1.5, 0.6) p=0.411
10-m walk (s)	9.0 (2.0)	9.1 (3.1)	8.8 (3.0)	8.9 (2.1)	8.7 (2.4)	8.6 (2.5)	-0.3 (-0.8, 0.3) p=0.322	-0.1 (-0.6, 0.5) p=0.802
Short Physical Performance Battery (score)	11 [2]	11 [2]	11 [2]	11 [2]	11 [1]	11 [2]	0 (0, 0), p=NA	0 (0, 1), p=NA
Stepping performance								
Choice stepping reaction time (s)	1.16 (0.20)	1.17 (0.17)	1.18 (0.23)	1.13 (0.18)	1.15 (0.19)	1.17 (0.18)	0.01 (-0.05, 0.06) p=0.744	0.03 (-0.03, 0.08) p=0.380
Inhibitory stepping reaction time (s)	1.32 (0.40)	1.32 (0.43)	1.32 (0.38)	1.26 (0.37)	1.36 (0.49)	1.29 (0.36)	0.10 (-0.04, 0.23), p=0.143	0.03 (-0.11, 0.17), p=0.645
Stroop stepping reaction time (s)	1.25 (0.42)	1.24 (0.39)	1.22 (0.39)	1.21 (0.34)	1.28 (0.38)	1.19 (0.34)	0.17 (0.16) p=0.302	0.26 (0.07) p=0.116
Cognitive performance and executive functions								
TMT-A (s)	31.9 [11.8]	27.5 [14.4]	39.6 [12.8]	29.8 [12.7]	29.7 [11.8]	28.4 [13.9]	1.8 (-0.7, 4.2), p=NA	0.6 (-2.0, 3.1), p=NA
TMT-B (s)	85.2 [50.7]	90.1 [54.3]	84.3 [55.8]	87.7 [43.2]	87.5 [53.5]	87.8 [51.8]	1.5 (-8.0, 11.0), p=NA	5.1 (-5.1, 15.3), p=NA
TMT-B min TMT-A (s)	54.8 [44.8]	60.5 [44.0]	56.2 [44.1]	55.3 [36.2]	55.9 [38.9]	59.7 [41.9]	-0.3 (-10.5, 9.6), p=NA	4.5 (-5.8, 15.0), p=NA
Victoria Stroop ratio	2.13 (0.87)	1.87 (0.92)	1.98 (0.91)	1.95 (0.74)	1.89 (0.89)	1.98 (0.96)	0.20 (-0.13, 0.53) p=0.224	0.18 (-0.15, 0.51) p=0.270
Victoria Stroop errors	4 [5]	3 [5]	3 [4]	3 [5]	3 [5]	2 [4]	0 (0, 0) p=NA	0 (0, 0) p=NA

Note: values are mean (standard deviation) or median [IQR]; p=NA indicates bootstrapped outcomes, which did not allow us to estimate p-values.

PPA: Physiological Profile Assessment; AP: anteroposterior; TMT: Trail-Making Test.

ONLINE SUPPLEMENTARY MATERIAL

Online Appendix 1: Negative binominal vs Poisson results

	Poisson			Negative binominal		
	<i>AIC</i>	<i>IRR (95% CI)</i>	<i>p</i>	<i>AIC</i>	<i>IRR (95% CI)</i>	<i>p</i>
Fall rate at 12-months	1220.50	0.84 (0.62, 1.13)	0.0710	1123.61	0.82 (0.66, 1.02)	0.2526
Fall rate at 24-months	1808.06	0.84 (0.72, 0.98)	0.0273	1530.52	0.86 (0.67, 1.11)	0.2516

Confidential: For Review Only

Online Appendix 2: Fall incidence rate ratios per pre-specified subgroups with statistical testing of differences.

12-months history of falls	No past falls n=307	Past falls n=192	Interaction (p-value)
Rate of falls at 12-months	0.78 (0.56, 1.09), <i>p</i> =0.142	0.77 (0.58, 1.01), <i>p</i> =0.063	0.931
Rate of falls at 24-months	0.91 (0.72, 1.15), <i>p</i> =0.438	0.67 (0.55, 0.83), <i>p</i> <0.001	0.058

Physiological fall risk	PPA ≤0.823 points n=245	PPA >0.823 points n=258	Interaction (p-value)
Rate of falls at 12-months	0.81 (0.58, 1.14), <i>p</i> =0.227	0.88 (0.66, 1.16), <i>p</i> =0.348	0.163
Rate of falls at 24-months	0.74 (0.58, 0.94), <i>p</i> =0.015	0.92 (0.76, 1.13), <i>p</i> =0.448	0.740

Executive function	TMT-B ≤86.4 s n=263	TMT-B >86.4 s n=240	Interaction (p-value)
Rate of falls at 12-months	0.93 (0.69, 1.25), <i>p</i> =0.637	0.75 (0.55, 1.03), <i>p</i> =0.074	0.718
Rate of falls at 24-months	0.86 (0.69, 1.06), <i>p</i> =0.166	0.81 (0.65, 1.02), <i>p</i> =0.072	0.331

Concern about falling	iconFES ≤49 n=244	iconFES >49 n=259	Interaction (p-value)
Rate of falls at 12-months	0.95 (0.68, 1.32), <i>p</i> =0.750	0.80 (0.60, 1.06), <i>p</i> = 0.120	0.447
Rate of falls at 24-months	0.91 (0.72, 1.15), <i>p</i> =0.422	0.80 (0.65, 0.99), <i>p</i> =0.042	0.438

Note: PPA: Physiological profile assessment, TMT-B: Trail Making Test part B, iconFES: Iconographical Fall Efficacy Scale. Cutpoints for PPA, TMT-B and iconFES are based on a median split.

Online Appendix 3: Change in subgroups (N=226) over first 12-months

Variable	Change in intervention compared to control group		Change in intervention compared to control group		Difference in change between subgroups	
	Beta (95% CI), p		Beta (95% CI), p		Beta (95% CI), p	
	0-6M	0-12M	0-6M	0-12M	0-6M	0-12M
12-month history of falls	No past falls n=91		Past falls n=131			
PPA score	-0.24 (-0.50, 0.02), p=0.076	-0.05 (-0.32, 0.21), p=0.690	-0.32 (-0.65, 0.01), p=0.057	-0.26 (-0.59, 0.08), p=0.135	-0.08 (-0.50, 0.34), p=0.704	-0.20 (-0.63, 0.22), p=0.354
TMT-B (s)	-1.7 (-13.5, 9.5), p=NA	5.5 (-6.8, 18.0), p=NA	12.5 (-6.6, 31.9), p=NA	11.2 (-8.6, 32.2), p=NA	14.2 (-7.5, 36.6), p=NA	5.7 (-18.3, 30.3), p=NA
IconFES	-2 (-4, 0), p=0.074	0 (-2, 3), p=0.754	0 (-3, 4), p=0.964	-2 (-6, 1), p=0.226	0 (-5, 4), p=0.866	-3 (-7, 2), p=0.247
Physiological fall risk	PPA ≤1.045 points n=113		PPA >1.045 points n=113			
PPA score	-0.64 (-0.91, -0.36), p<0.0001	-0.37 (-0.64, -0.09), p=0.010	-0.11 (-0.34, 0.12), p=0.335	-0.04 (0.12), p=0.747	0.52 (0.17, 0.88), p=0.004	0.33 (0.69, -0.03), p=0.077
TMT-B (s)	-1.67 (-13.29, 10.47), p=NA	3.09 (-15.01, 19.72), p=NA	7.26 (-8.59, 22.53), p=NA	9.71 (-3.69, 23.90), p=NA	8.93 (-10.97, 28.06), p=NA	6.62 (-15.76, 27.70), p=NA
iconFES	-1 (-3, 1), p=0.488	-2 (-5, 1), p=0.272	2 (-1, 5), p=0.144	1 (-2, 4), p=0.510	4 (1, -8), p=0.097	3 (2, 7), p=0.217
Executive function	TMT-B >86.85 s n=113		TMT-B ≤86.85 s n=113			
PPA score	-0.14 (-0.42, 0.15), p=0.345	-0.03 (-0.31, 0.27), p=0.859	-0.42 (-0.71, -0.13), p=0.004	-0.24 (-0.53, 0.05), p=0.103	-0.28 (-0.69, 0.12), p=0.174	-0.21 (-0.62, 0.20), p=0.311
TMT-B (s)	12.3 (-5.7, 28.6), p=NA	16.4 (-3.0, 35.5), p=NA	-3.8 (-12.6, 5.0), p=NA	0.61 (-9.9, 10.2), p=NA	-16.0 (-35.6, 4.3), p=NA	-15.8 (-36.7, -5.8), p=NA
iconFES	2 (-1, 5), p=0.262	0 (-3, 4), p=0.839	-1 (-3, 1), p=0.332	-1 (-4, 2), p=0.474	-3 (-7, 2), p=0.205	-1 (-6, 3), p=0.521
Concern about falling	iconFES >50 n=113		iconFES ≤50 n=113			
PPA score	-0.36 (-0.64, -0.07), p=0.014	-0.13 (-0.41, 0.16), p=0.389	-0.19 (-0.48, 0.11), p=0.212	-0.14 (0.15), p=0.379	0.17 (-0.24, 0.58), p=0.420	-0.01 (-0.42, 0.40), p=0.967
TMT-B (s)	10.2 (-6.1, 26.8), p=NA	17.4 (0.7, 35.1), p=NA	-5.0 (-16.5, 5.9), p=NA	-3.1 (-15.6, 8.4), p=NA	-15.2 (-34.9, 3.9), p=NA	-20.5 (-41.8, 0.5), p=NA
iconFES	1 (-2, 4), p=0.356	2 (-1, 5), p=0.213	3 (0, 5), p=0.019	-3 (-6, 0), p=0.058	2 (2, 7), p=0.265	-5 (-9, -1), p=0.027

Note: PPA: Physiological profile assessment, TMT-B: Trail Making Test part B, iconFES: Iconographical Fall Efficacy Scale. Cutpoints for PPA, TMT-B and iconFES are based on a median split. p=NA indicates bootstrapped outcomes, which did not allow us to estimate p-values.

Online Appendix 4: PEDro assessment

Item	Response	Score	
1	Eligibility criteria were specified	Page 6	1
2	Subjects were randomly allocated to groups (in a crossover study, subjects were randomly allocated an order in which treatments were received)	Page 6	1
3	Allocation was concealed	Page 6	1
4	The groups were similar at baseline regarding the most important prognostic indicators	Table 1	1
5	There was blinding of all subjects	No, not possible in an exercise vs. control program	0
6	There was blinding of all therapists who administered the therapy	N/A, the programme was unsupervised	1
7	There was blinding of all assessors who measured at least one key outcome	Page 6	1
8	Measures of at least one key outcome were obtained from more than 85% of the subjects initially allocated to groups	Page 9	1
9	All subjects for whom outcome measures were available received the treatment or control condition as allocated or, where this was not the case, data for at least one key outcome was analysed by "intention to treat"	Page 8	1
10	The results of between-group statistical comparisons are reported for at least one key outcome	Figure 2, Table 2 & 3	1
11	The study provides both point measures and measures of variability for at least one key outcome	Figure 2, Table 2 & 3	1
Total Score			10




Figure 1: Flowchart of study recruitment and retention.




Figure 2: Effect on rate of falls and faller status. Primary outcomes are bolded, values indicate incidence rate ratio (IRR) or relative risk (RR) with corresponding 95% confidence interval (95% CI). Vertical line indicates no difference between the groups (i.e. IRR or RR of 1). CACE shows complier average causal effect.

ONLINE SUPPLEMENTARY MATERIAL

Online Appendix 1: Negative binominal vs Poisson results

	Poisson			Negative binominal		
	<i>AIC</i>	<i>IRR (95% CI)</i>	<i>p</i>	<i>AIC</i>	<i>IRR (95% CI)</i>	<i>p</i>
Fall rate at 12-months	1220.50	0.84 (0.62, 1.13)	0.0710	1123.61	0.82 (0.66, 1.02)	0.2526
Fall rate at 24-months	1808.06	0.84 (0.72, 0.98)	0.0273	1530.52	0.86 (0.67, 1.11)	0.2516

Confidential: For Review Only

Online Appendix 2: Fall incidence rate ratios per pre-specified subgroups with statistical testing of differences.

12-months history of falls	No past falls n=307	Past falls n=192	Interaction (p-value)
Rate of falls at 12-months	0.78 (0.56, 1.09), <i>p</i> =0.142	0.77 (0.58, 1.01), <i>p</i> =0.063	0.931
Rate of falls at 24-months	0.91 (0.72, 1.15), <i>p</i> =0.438	0.67 (0.55, 0.83), <i>p</i> <0.001	0.058

Physiological fall risk	PPA ≤0.823 points n=245	PPA >0.823 points n=258	Interaction (p-value)
Rate of falls at 12-months	0.81 (0.58, 1.14), <i>p</i> =0.227	0.88 (0.66, 1.16), <i>p</i> =0.348	0.163
Rate of falls at 24-months	0.74 (0.58, 0.94), <i>p</i> =0.015	0.92 (0.76, 1.13), <i>p</i> =0.448	0.740

Executive function	TMT-B ≤86.4 s n=263	TMT-B >86.4 s n=240	Interaction (p-value)
Rate of falls at 12-months	0.93 (0.69, 1.25), <i>p</i> =0.637	0.75 (0.55, 1.03), <i>p</i> =0.074	0.718
Rate of falls at 24-months	0.86 (0.69, 1.06), <i>p</i> =0.166	0.81 (0.65, 1.02), <i>p</i> =0.072	0.331

Concern about falling	iconFES ≤49 n=244	iconFES >49 n=259	Interaction (p-value)
Rate of falls at 12-months	0.95 (0.68, 1.32), <i>p</i> =0.750	0.80 (0.60, 1.06), <i>p</i> = 0.120	0.447
Rate of falls at 24-months	0.91 (0.72, 1.15), <i>p</i> =0.422	0.80 (0.65, 0.99), <i>p</i> =0.042	0.438

Note: PPA: Physiological profile assessment, TMT-B: Trail Making Test part B, iconFES: Iconographical Fall Efficacy Scale. Cutpoints for PPA, TMT-B and iconFES are based on a median split.

Online Appendix 3: Change in subgroups (N=226) over first 12-months

Variable	Change in intervention compared to control group		Change in intervention compared to control group		Difference in change between subgroups	
	Beta (95% CI), p		Beta (95% CI), p		Beta (95% CI), p	
	0-6M	0-12M	0-6M	0-12M	0-6M	0-12M
12-month history of falls	No past falls n=91		Past falls n=131			
PPA score	-0.24 (-0.50, 0.02), p=0.076	-0.05 (-0.32, 0.21), p=0.690	-0.32 (-0.65, 0.01), p=0.057	-0.26 (-0.59, 0.08), p=0.135	-0.08 (-0.50, 0.34), p=0.704	-0.20 (-0.63, 0.22), p=0.354
TMT-B (s)	-1.7 (-13.5, 9.5), p=NA	5.5 (-6.8, 18.0), p=NA	12.5 (-6.6, 31.9), p=NA	11.2 (-8.6, 32.2), p=NA	14.2 (-7.5, 36.6), p=NA	5.7 (-18.3, 30.3), p=NA
IconFES	-2 (-4, 0), p=0.074	0 (-2, 3), p=0.754	0 (-3, 4), p=0.964	-2 (-6, 1), p=0.226	0 (-5, 4), p=0.866	-3 (-7, 2), p=0.247
Physiological fall risk	PPA ≤1.045 points n=113		PPA >1.045 points n=113			
PPA score	-0.64 (-0.91, -0.36), p<0.0001	-0.37 (-0.64, -0.09), p=0.010	-0.11 (-0.34, 0.12), p=0.335	-0.04 (0.12), p=0.747	0.52 (0.17, 0.88), p=0.004	0.33 (0.69, -0.03), p=0.077
TMT-B (s)	-1.67 (-13.29, 10.47), p=NA	3.09 (-15.01, 19.72), p=NA	7.26 (-8.59, 22.53), p=NA	9.71 (-3.69, 23.90), p=NA	8.93 (-10.97, 28.06), p=NA	6.62 (-15.76, 27.70), p=NA
iconFES	-1 (-3, 1), p=0.488	-2 (-5, 1), p=0.272	2 (-1, 5), p=0.144	1 (-2, 4), p=0.510	4 (1, -8), p=0.097	3 (2, 7), p=0.217
Executive function	TMT-B >86.85 s n=113		TMT-B ≤86.85 s n=113			
PPA score	-0.14 (-0.42, 0.15), p=0.345	-0.03 (-0.31, 0.27), p=0.859	-0.42 (-0.71, -0.13), p=0.004	-0.24 (-0.53, 0.05), p=0.103	-0.28 (-0.69, 0.12), p=0.174	-0.21 (-0.62, 0.20), p=0.311
TMT-B (s)	12.3 (-5.7, 28.6), p=NA	16.4 (-3.0, 35.5), p=NA	-3.8 (-12.6, 5.0), p=NA	0.61 (-9.9, 10.2), p=NA	-16.0 (-35.6, 4.3), p=NA	-15.8 (-36.7, -5.8), p=NA
iconFES	2 (-1, 5), p=0.262	0 (-3, 4), p=0.839	-1 (-3, 1), p=0.332	-1 (-4, 2), p=0.474	-3 (-7, 2), p=0.205	-1 (-6, 3), p=0.521
Concern about falling	iconFES >50 n=113		iconFES ≤50 n=113			
PPA score	-0.36 (-0.64, -0.07), p=0.014	-0.13 (-0.41, 0.16), p=0.389	-0.19 (-0.48, 0.11), p=0.212	-0.14 (0.15), p=0.379	0.17 (-0.24, 0.58), p=0.420	-0.01 (-0.42, 0.40), p=0.967
TMT-B (s)	10.2 (-6.1, 26.8), p=NA	17.4 (0.7, 35.1), p=NA	-5.0 (-16.5, 5.9), p=NA	-3.1 (-15.6, 8.4), p=NA	-15.2 (-34.9, 3.9), p=NA	-20.5 (-41.8, 0.5), p=NA
iconFES	1 (-2, 4), p=0.356	2 (-1, 5), p=0.213	3 (0, 5), p=0.019	-3 (-6, 0), p=0.058	2 (2, 7), p=0.265	-5 (-9, -1), p=0.027

Note: PPA: Physiological profile assessment, TMT-B: Trail Making Test part B, iconFES: Iconographical Fall Efficacy Scale. Cutpoints for PPA, TMT-B and iconFES are based on a median split. p=NA indicates bootstrapped outcomes, which did not allow us to estimate p-values.

Online Appendix 4: PEDro assessment

Item	Response	Score	
1	Eligibility criteria were specified	Page 6	1
2	Subjects were randomly allocated to groups (in a crossover study, subjects were randomly allocated an order in which treatments were received)	Page 6	1
3	Allocation was concealed	Page 6	1
4	The groups were similar at baseline regarding the most important prognostic indicators	Table 1	1
5	There was blinding of all subjects	No, not possible in an exercise vs. control program	0
6	There was blinding of all therapists who administered the therapy	N/A, the programme was unsupervised	1
7	There was blinding of all assessors who measured at least one key outcome	Page 6	1
8	Measures of at least one key outcome were obtained from more than 85% of the subjects initially allocated to groups	Page 9	1
9	All subjects for whom outcome measures were available received the treatment or control condition as allocated or, where this was not the case, data for at least one key outcome was analysed by "intention to treat"	Page 8	1
10	The results of between-group statistical comparisons are reported for at least one key outcome	Figure 2, Table 2 & 3	1
11	The study provides both point measures and measures of variability for at least one key outcome	Figure 2, Table 2 & 3	1
Total Score			10